Skip to main content

Table 1 Patient characteristics

From: Predictive value of quantitative 18F-FDG-PET radiomics analysis in patients with head and neck squamous cell carcinoma

 

Training cohort

Validation cohort

 

Number (%)

Number (%)

Patients total

103

71

No of male patients

76 (73.8%)

53 (75.7%)

Age, years (mean, IQR)

62.3 (57.3–67.8)

63.3 (57.8–69.3)

Mean radiation dose, Gy

70

70

Chemotherapy

 Cisplatin

88 (85.4%)

57 (80%)

 Cetuximab

15 (14.6%)

14 (20%)

T-stage

 2

46 (44.7%)

25 (35.2%)

 3

24 (23.3%)

19 (26.8%)

 4

33 (32%)

27 (38%)

N-stage

 0

14 (13.6%)

11 (15.5%)

 1

13 (12.6%)

15 (21.1%)

 2

75 (72.8%)

45 (63.4%)

 3

1 (1%)

0 (0%)

HPV-status

 Positive

39 (37.9%)

26 (36.6%)

 Negative

64 (62.1%)

45 (63.4%)

Tumor site

 Oropharynx

74 (71.8%)

51 (71.8%)

 Hypopharynx

29 (28.2%)

20 (28.2%)

Overall alcohol history score (SD)

1.91 (1.19)

1.72 (1.24)

Smoking pack years, (IQR)

22.7 (18.2–38.9)

23.5 (19.3–41.3)

Follow-up time (mean, IQR)

31.5 (20.7–44.5)

26.4 (19.8–34.1)

Recurrence

27 (26.2%)

19 (27.1%)

Metastasis

10 (9.7%)

18 (25.7%)

Death

37 (35.9%)

22 (31.4%)

IQR: interquartile range